Public Private Partnerships: Advance rational drug repositioning and combination therapy

Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector to advance rational drug repositioning and combination therapy based on translational bioinformatics and network pharmacology approaches and to explore opportunities for new public-private partnerships to facilitate drug rescue/repurposing and combination therapy.

2030 PAR-20-156: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01 Clinical Trial Optional) 14.J In Progress Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector... DN 2012 AD Summit: 4A, 4B, 4C, and 4D News: NIH Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention News: NIH Alzheimer’s Disease Research Summit 2015: Path to Treatment and Prevention News: NIH Alzheimer’s Disease Research Summit 2018: Path to Treatment and Prevention Public Private Partnerships 2016

  • Development of recommendations for rational repositioning and combination therapy development.
  • Development, negotiation, and implementation of appropriate agreements among the stakeholders involved in repositioning and combination therapy of drugs for AD and related dementias.
  • These agreements should address legal issues, intellectual property rights, and liability to expedite rigorous clinical testing of repurposed drugs.

Summary of Key Accomplishments

Milestone goals are supported by the proceedings of the NIH Alzheimer’s Research Summits 2015, 2018 and 2021. Each of these Summits delivered a series of research recommendations related to the advancement of data-driven drug repurposing and combination therapy development. These recommendations led to the launch of a targeted funding initiative: “Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for AD/ADRD.”

The key accomplishments summary is current as of July 2022.